keyword
MENU ▼
Read by QxMD icon Read
search

Wearable Defibrillator

keyword
https://www.readbyqxmd.com/read/29678779/experience-with-the-wearable-cardioverter-defibrillator-in-older-patients-results-from-the-prospective-registry-of-patients-using-the-wearable-cardioverter-defibrillator-wearit-ii-registry
#1
Usama A Daimee, Katherine Vermilye, Arthur J Moss, Ilan Goldenberg, Helmut U Klein, Scott McNitt, Wojciech Zareba, Valentina Kutyifa
BACKGROUND: Use of the wearable cardioverter-defibrillator (WCD) in older patients has not been described previously. OBJECTIVES: To assess WCD wear time, risk of arrhythmia events during WCD use, and implantable cardioverter-defibrillator (ICD) implantation rates following end of WCD use in patients with age ≥65 vs. <65 years. METHODS: We stratified 1,732 patients with ischemic and non-ischemic cardiomyopathies from the WEARIT-II registry into two sub-groups by age: ≥65 and <65 years...
April 17, 2018: Heart Rhythm: the Official Journal of the Heart Rhythm Society
https://www.readbyqxmd.com/read/29660751/-exposure-therapy-with-the-help-of-a-wearable-defibrillator-device-used-in-the-treatment-of-severe-obsessive-compulsive-disorder-and-congenital-lqts-an-example-for-interdisciplinary-treatment
#2
Fabian Sinowatz, Clemens Jilek, Ulrich Voderholzer, Ulrich Cuntz, Martin Greetfeld, Petra Hopfner, Jürgen Pache
We report on a case of a young female suffering from both obsessive-compulsive disorder (OCD) and a severe underlying cardiac disease. Due to the somatic comorbidity, treatment according to guidelines with exposure and reaction prevention was not initially conducted, due to potentially fatal risks to the patient. However, through collaboration with a cardiology clinic, we were able to find an innovative solution which allowed for the continuation of the exposure therapy. This case report demonstrates a successful interdisciplinary collaboration and is intended to sensitize the reader to the need for checking for somatic contraindications before conducting exposure therapy...
April 16, 2018: Psychotherapie, Psychosomatik, Medizinische Psychologie
https://www.readbyqxmd.com/read/29566033/management-of-sudden-cardiac-death-in-cardiac-sarcoidosis-using-the-wearable-cardioverter-defibrillator
#3
Dirk Skowasch, Steven Ringquist, Georg Nickenig, René Andrié
BACKGROUND: Patients with cardiac sarcoidosis are at increased risk of ventricular tachycardia/fibrillation. OBJECTIVE: We tested the hypothesis that the wearable cardioverter defibrillator can be used to mitigate the risk of sudden cardiac death among cardiac sarcoidosis patients. METHODS: A retrospective review of the commercial database identified cardiac sarcoidosis patients who wore the wearable cardioverter defibrillator. Evidence for cardiac sarcoidosis diagnosis as well as demographic, co-morbidity and left ventricular ejection fraction were provided by patient clinical records...
2018: PloS One
https://www.readbyqxmd.com/read/29544442/therapy-optimization-in-patients-with-heart-failure-the-role-of-the-wearable-cardioverter-defibrillator-in-a-real-world-setting
#4
Susanne Röger, Stefanie L Rosenkaimer, Anna Hohneck, Siegfried Lang, Ibrahim El-Battrawy, Boris Rudic, Erol Tülümen, Ksenija Stach, Jürgen Kuschyk, Ibrahim Akin, Martin Borggrefe
BACKGROUND: The wearable cardioverter-defibrillator (WCD) has emerged as a valuable tool to temporarily protect patients at risk for sudden cardiac death (SCD). The aim of this study was to determine the value of the WCD for therapy optimization of heart failure patients. METHODS: One hundred five consecutive patients that received WCD between 4/2012 and 9/2016 were included in the study. All patients were followed for clinical outcome and echocardiographic parameters during WCD therapy and had continued follow-up after WCD therapy, irrespective of subsequent implantable cardioverter-defibrillator (ICD) implantation...
March 15, 2018: BMC Cardiovascular Disorders
https://www.readbyqxmd.com/read/29445060/clinical-usefulness-of-wearable-cardioverter-defibrillator-wcd-and-current-understanding-of-its-clinical-indication-in-japan
#5
Shinichi Niwano, Yukio Sekiguchi, Yosuke Ishii, Yuki Iwasaki, Ritsushi Kato, Hideo Okamura, Masahiko Takagi, Takashi Kurita, Takashi Nitta
Prevention of sudden cardiac death (SCD) has become an important issue in today's cardiovascular field, together with various developments in secondary prevention of basic cardiac diseases. The importance of the implantable cardioverter defibrillator (ICD) is now widely accepted because it has exhibited significant improvement in patients' prognoses in ischemic and non-ischemic cardiovascular diseases. However, there is an unignorable gap between the ICD indication in the guidelines and real-world high-risk patients for SCD, especially in the acute recovery phase of cardiac injury...
February 14, 2018: Circulation Journal: Official Journal of the Japanese Circulation Society
https://www.readbyqxmd.com/read/29428131/use-of-the-wearable-cardioverter-defibrillator-as-a-bridge-to-implantable-cardioverter-defibrillator
#6
REVIEW
Jonathan Weinstock
The wearable cardioverter defibrillator has been shown to be effective in terminating ventricular arrhythmias in patients at risk for sudden cardiac death. There are numerous scenarios in which implant of a permanent implantable cardioverter defibrillator is temporarily contraindicated or not advisable and a wearable cardioverter defibrillator may be beneficial. There are no prospective randomized studies published that provide conclusive guidance toward the use of the wearable cardioverter defibrillator, and thus, patient management needs to be individualized based on the available data...
March 2018: Cardiac Electrophysiology Clinics
https://www.readbyqxmd.com/read/29405947/class-ic-antiarrhythmic-drugs-for-suspected-premature-ventricular-contraction-induced-cardiomyopathy
#7
Matthew C Hyman, Danielle Mustin, Gregory Supple, Robert D Schaller, Pasquale Santangeli, Jeffrey Arkles, David Lin, Daniele Muser, Sanjay Dixit, Saman Nazarian, Andrew E Epstein, David J Callans, Francis E Marchlinski, David S Frankel
BACKGROUND: Class IC antiarrhythmic drugs (IC-AADs) can effectively suppress premature ventricular contractions (PVCs). However, IC-AADs increase mortality in patients with PVCs and left ventricular dysfunction after myocardial infarction. Whether IC-AADs can be safely used to treat premature ventricular contraction-induced cardiomyopathy (PVC-CM) remains to be established. OBJECTIVE: The purpose of this study was to determine the safety and efficacy of IC-AADs in patients suspected of having PVC-CM...
February 2018: Heart Rhythm: the Official Journal of the Heart Rhythm Society
https://www.readbyqxmd.com/read/29277221/wearable-cardioverter-defibrillator-the-lifevest-device-design-limitations-and-areas-of-improvement
#8
Manyoo Agarwal, Dennis Narcisse, Nader Khouzam, Rami N Khouzam
Sudden cardiac death is a potentially fatal clinical event demanding use of emergent intervention such as defibrillation. Over the last 1 decade, development of devices such as implantable and wearable cardioverter defibrillators (WCD) has provided new avenues in the management of sudden cardiac death. Several clinical studies have commented on the therapeutic and preventive aspect of WCD, however, literature describing the device functioning and limitations is limited. In this review study, we describe the technical aspects and limitations of WCD with a focus on identifying potential areas of improvement and framework for future research studies...
February 2018: Current Problems in Cardiology
https://www.readbyqxmd.com/read/29251759/ventricular-tachycardia-successfully-treated-with-wearable-cardioverter-defibrillator
#9
Marcin Grabowski, Monika Gawałko, Marcin Michalak, Andrzej Cacko, Grzegorz Opolski
No abstract text is available yet for this article.
2017: Kardiologia Polska
https://www.readbyqxmd.com/read/29234842/-patients-with-a-wearable-cardioverter-defibrillator-wcd-prescription-function-and-rehabilitation-support
#10
REVIEW
A Schlitt, M Guha, M Noutsias, H H Klein, H U Klein
Assessment of a permanent risk of life-threatening ventricular arrhythmia in patients with severely reduced left ventricular ejection fraction (LVEF <35%), e. g. after myocarditis, dilated cardiomyopathy, acute myocardial infarction, in patients with postpartum cardiomyopathy or implantable cardioverter-defibrillator (ICD) and cardiac resynchronization treatment plus defibrillator (CRT-D) infection with temporary explantation of the system is a medical challenge. This is time-consuming and unsafe because life-threatening ventricular arrhythmias may occur during the time of risk assessment...
December 12, 2017: Herz
https://www.readbyqxmd.com/read/29180909/wearable-cardioverter-defibrillators-for-the-prevention-of-sudden-cardiac-arrest-a-health-technology-assessment-and-patient-focus-group-study
#11
Sabine Ettinger, Michal Stanak, Piotr Szymański, Claudia Wild, Romana Tandara Haček, Darija Erčević, Renata Grenković, Mirjana Huić
Aim: To summarize the evidence on clinical effectiveness and safety of wearable cardioverter defibrillator (WCD) therapy for primary and secondary prevention of sudden cardiac arrest in patients at risk. Methods: We performed a systematic literature search in databases including MEDLINE via OVID, Embase, the Cochrane Library, and CRD (DARE, NHS-EED, HTA). The evidence obtained was summarized according to GRADE methodology. A health technology assessment (HTA) was conducted using the HTA Core Model® for rapid relative effectiveness assessment...
2017: Medical Devices: Evidence and Research
https://www.readbyqxmd.com/read/29178898/the-wearable-cardioverter-defibrillator-as-a-bridge-to-reimplantation-in-patients-with-icd-or-crt-d-related-infections
#12
L Castro, S Pecha, M Linder, J Vogler, N Gosau, C Meyer, S Willems, H Reichenspurner, S Hakmi
BACKGROUND: The approach to treat device infection in patients with implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D) is a challenging procedure. Optimal treatment is complete extraction of the infected device. To protect these patients from sudden cardiac arrest while waiting for reimplantation and to avoid recurrent infection, a wearable cardioverter defibrillator (WCD) seems to be a valuable solution. Therefore, we investigated the management and outcome of patients with ICD or CRT-D infections using the WCD as a bridge to re-implantation after lead extraction procedures...
November 25, 2017: Journal of Cardiothoracic Surgery
https://www.readbyqxmd.com/read/29153771/outcome-of-patients-with-in-hospital-ventricular-tachycardia-and-ventricular-fibrillation-arrest-while-using-a-wearable-cardioverter-defibrillator
#13
Kenneth A Ellenbogen, Chingping Wan, David M Shavelle
In-hospital sudden cardiac arrests occurring during nighttime and weekend hours or within unmonitored hospital areas have been reported to have a poorer outcomes than monitored cardiac arrest. This study sought to assess the outcome of in-hospital ventricular tachycardia (VT) and ventricular fibrillation (VF) arrest by time of day, day of week, and within-hospital location when using a wearable cardioverter defibrillator (WCD). We retrospectively identified and reviewed consecutive in-hospital VT/VF arrests from January 2011 to May 2015 experienced by patients wearing a WCD using the manufacturer's postmarket registry...
January 15, 2018: American Journal of Cardiology
https://www.readbyqxmd.com/read/29124430/oversensing-of-the-wearable-cardioverter-defibrillator-during-bipolar-ventricular-stimulation
#14
Martin Manninger, Tanja Odeneg, Friedrich Fruhwald, Helmut Brussee, Daniel Scherr
The wearable cardioverter defibrillator (WCD) is a temporary treatment option for patients with potentially reversible risk of sudden cardiac death. This case demonstrates a pitfall during WCD usage in a pacemaker-dependent patient as well as a possible solution allowing continuation of WCD therapy. Bipolar stimulation may lead to double counting of the WCD detection algorithm resulting in false alarm or inappropriate therapy.
December 2017: Wiener Klinische Wochenschrift
https://www.readbyqxmd.com/read/29072998/real-world-utilization-and-impact-of-the-wearable-cardioverter-defibrillator-in-a-community-setting
#15
Aditi Naniwadekar, Talal Alnabelsi, Kamal Joshi, Edinrin Obasare, Allan Greenspan, Sumeet Mainigi
INTRODUCTION: The wearable cardioverter-defibrillator (WCD) is used in patients at risk for sudden cardiac death (SCD) but not immediate candidates for intracardiac defibrillator (ICD) implantation. METHODS: We performed a single center retrospective study of patients prescribed WCD upon hospital discharge from January 2002 to October 2015. Clinical characteristics were obtained from the hospital electronic database and device data from Zoll LifeVest database. RESULTS: Of 140 patients, 62% were men, 85...
May 2017: Indian Pacing and Electrophysiology Journal
https://www.readbyqxmd.com/read/29071387/-ventricular-arrhythmias-what-has-been-confirmed-in-therapy
#16
REVIEW
D Duncker, J Bauersachs, C Veltmann
Ventricular arrhythmias include a wide range of potentially benign single ventricular premature contractions to ventricular tachycardia and ventricular fibrillation with a risk for sudden cardiac death. The diagnosis of ventricular arrhythmia is made by 12-lead electrocardiogram, 24 h Holter monitoring, an external or implantable loop recorder, or during in-hospital monitoring. Especially the diagnosis of wide complex tachycardias is challenging in terms of differentiating between ventricular tachycardia and supraventricular tachycardia with aberrant atrioventricular conduction...
December 2017: Der Internist
https://www.readbyqxmd.com/read/29064577/wearable-cardioverter-defibrillators-in-schools-a-guide-for-parents-and-educators
#17
Ashley E Burch, David S Spar, Samuel F Sears
Keeping children safe is a goal for everyone. To stay safe, some children need a wearable cardioverter defibrillator (WCD). WCDs protect individuals who are at risk for life-threatening arrhythmias. The LifeVest® (ZOLL, Pittsburgh, PA, USA) is a WCD that identifies, records, and treats potentially life-threatening abnormal heartbeats, or arrhythmias. The WCD will provide electrical energy to the heart with up to five high-energy shocks if a potentially dangerous cardiac arrhythmia is detected. This type of arrhythmia, if not treated within a short time period (less than 2 minutes), can result in disruption of blood flow to the brain and other vital organs (that is, a sudden cardiac arrest), and death can occur within minutes...
December 2017: Pacing and Clinical Electrophysiology: PACE
https://www.readbyqxmd.com/read/28993851/usefulness-of-the-wcd-in-patients-with-suspected-tachymyopathy
#18
Julia W Erath, Mate Vamos, Alexander P Benz, Stefan H Hohnloser
AIMS: The wearable cardioverter defibrillator (WCD) is used for temporary protection of patients deemed to be at high risk for sudden death. There is limited experience regarding the clinical development of patients with tachymyopathy. We aimed to evaluate the clinical development of tachymyopathy patients protected with a WCD in a single-center non-randomized patient cohort. METHODS AND RESULTS: We fitted 130 consecutive patients deemed to be at high risk for ventricular tachyarrhythmias with the WCD...
January 2018: Clinical Research in Cardiology: Official Journal of the German Cardiac Society
https://www.readbyqxmd.com/read/28984287/the%C3%A2-lifevest-wearable-defibrillator-for-noninvasive-prevention-of-sudden-arrhythmic-death-syndrome-the%C3%A2-first-polish-case-of-an-adequate-lifevest-intervention
#19
Michał Chudzik, Łukasz Szyda, Bożena Urbanek, Jerzy K Wranicz, Jarosław D Kasprzak
No abstract text is available yet for this article.
September 29, 2017: Polish Archives of Internal Medicine
https://www.readbyqxmd.com/read/28969980/ventricular-arrhythmia-occurrence-and-compliance-in-patients-treated-with-the-wearable-cardioverter-defibrillator-following-percutaneous-coronary-intervention
#20
Jérémie Barraud, Pauline Pinon, Marc Laine, Jennifer Cautela, Morgane Orabona, Linda Koutbi, Johan Pinto, Franck Thuny, Frederic Franceschi, Franck Paganelli, Laurent Bonello, Michaël Peyrol
BACKGROUND: The wearable cardioverter defibrillator (WCD) is a life-saving therapy in patients with high risk of arrhythmic death. We aimed to evaluate ventricular arrhythmia (VA) occurrence rate and compliance with the WCD during the first 90 days following myocardial revascularisation with percutaneous coronary intervention (PCI) in patients with left ventricular ejection fraction (LVEF) <30%. METHODS: From September 2015 to November 2016, clinical characteristics, WCD recordings and compliance data of the aforementioned subset of patients were prospectively collected...
September 25, 2017: Heart, Lung & Circulation
keyword
keyword
86356
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"